Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmicell Eyes US After Promising Cirrhosis Cell Therapy Results

Executive Summary

South Korea's Pharmicell is taking steady steps towards commercializing a stem cell therapy for alcoholic liver cirrhosis, an area with outstanding needs, following a successful Phase II domestic trial that lays the ground for a Phase III program and the start of US clinical development.

Advertisement

Related Content

Govt Support Bolsters Pharmicell’s Stem Cell Therapy Plans

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel